Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mazindol controlled release - NLS Pharmaceutics Ltd

Next Previous
Drug Profile

Mazindol controlled release - NLS Pharmaceutics Ltd

Alternative Names: Mazindol extended release - NLS Pharmaceutics Ltd; NLS 0; NLS 1; NLS-10; NLS-13; NLS-2; Nolazol; Quilience

Latest Information Update: 02 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NLS Pharma Ltd
  • Developer NLS Pharmaceutics Ltd
  • Class 3-ring heterocyclic compounds; Anorectics; Behavioural disorder therapies; Drug withdrawal therapies; Imidazoles; Isoindoles; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Orexin receptor type 2 agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Attention-deficit hyperactivity disorder; Idiopathic hypersomnia; Narcolepsy
  • No development reported Opioid-related disorders

Most Recent Events

  • 21 May 2025 Pharmacodynamic data from the preclinical study (KO-943) in opioid related disorders released by NLS Pharmaceuticals
  • 21 May 2025 NLS Pharmaceuticals plans the NLS-6002 clinical trial for Opioid related disorders in May 2025
  • 15 Apr 2025 Pharmacodynamics data from the preclinical trial in Attention-deficit hyperactivity disorder and Narcolepsy released by NLS Pharmaceutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top